Vaxart (OTCMKTS:VXRT) Stock Price Passes Above Fifty Day Moving Average – Should You Sell?

Vaxart, Inc. (OTCMKTS:VXRT)’s stock price crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.53 and traded as high as $0.6399. Vaxart shares last traded at $0.6380, with a volume of 212,247 shares traded.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Vaxart to a “buy” rating in a research note on Friday, January 23rd. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Vaxart currently has a consensus rating of “Buy” and an average price target of $2.00.

Vaxart Trading Up 8.1%

The company has a market capitalization of $153.43 million, a P/E ratio of -2.77 and a beta of 1.19. The firm’s 50 day moving average price is $0.53 and its two-hundred day moving average price is $0.42.

Institutional Investors Weigh In On Vaxart

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. grew its holdings in shares of Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 70,568 shares in the last quarter. Jones Financial Companies Lllp boosted its position in Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after purchasing an additional 478,111 shares during the last quarter. Goldman Sachs Group Inc. bought a new position in Vaxart in the first quarter valued at approximately $31,000. Creative Planning acquired a new position in shares of Vaxart during the 2nd quarter worth approximately $33,000. Finally, Marshall Wace LLP bought a new stake in shares of Vaxart during the 2nd quarter worth approximately $794,000. 18.05% of the stock is owned by institutional investors.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.